Amgen ends studies of gastric cancer drug

NEW YORK- Biotech drugmaker Amgen said Monday it is ending late-stage trials of its gastric cancer treatment rilotumumab because patients who took the drug were more likely to die. Amgen said more patients died after treatment with rilotumumab and chemotherapy than with chemotherapy alone. Amgen is terminating that trial and one other.